drugset

drugset / Trial / NCT00344110

Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension

NCT00344110 ↗

Phase 3 Completed 768 enrolled Novartis

RandomizedParallel-groupDouble-blindTreatment

Summary

Assessing efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension

Timeline

Start: 2006-06
Primary completion: 2007-04
Completion: 2007-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aliskiren	Small molecule	150 mg	—

Indications